Author:
Adams Rebecca,Chopra Priya,Miranda Richard,Calderon Aaron
Abstract
Neurotoxicity is an unusual side effect of carbapenems, and it has been reported most commonly presenting as seizures, encephalopathy and hallucinations. Ertapenem neurotoxicity most classically presents as seizures in patients with end-stage renal disease (estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2). We present a patient with a baseline eGFR of 30–59 mL/min/1.73 m2 with acute kidney injury who developed non-seizure neurotoxicity after ertapenem exposure. This patient is a middle-aged Caucasian man who received intravenous ertapenem for treatment of empyema. Although the empyema improved, he developed delirium beginning on day 7 of ertapenem. The delirium progressed to constant agitation and visual hallucinations requiring transfer to the intensive care unit with eventual intubation for airway protection. No improvement in mental status was observed with cessation of other medications. Ertapenem was discontinued and within 24 hours, he was extubated, and his mental status returned to baseline. He was discharged from the hospital the following day. The timely resolution after ertapenem discontinuation makes ertapenem-induced encephalopathy the most likely explanation for this patient’s course.
Reference17 articles.
1. An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?;Owens;Crit Care,2008
2. Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties;Hammond;J Antimicrob Chemother,2004
3. Ertapenem-associated psychosis and encephalopathy;Oo;Intern Med J,2014
4. Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism;Shea;Int J Clin Pharm,2013
5. Central nervous system toxicity associated with ertapenem use;Duquaine;Ann Pharmacother,2011
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献